A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

• Главные авторы: Yan Chen (Автор), Bo Jiang (Автор), Yuange He (Автор), Chu Zhang (Автор), Wenjie Zhou (Автор), Cheng Fang (Автор), Dejian Gu (Автор), Minxia Zhang (Автор), Mei Ji (Автор), Juntao Shi (Автор), Xin Yang (Автор)
• Формат: ‌
• Опубликовано: BMC, 2022-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background Targeted therapy has revolutionized the treatment of patients with malignancies harboring mutations in driver genes and has brought a favorable survival benefit to the population with actionable oncogenic mutations. In recent years, the MET exon14 skipping mutation has been recog...